784-P: Once-Weekly Semaglutide in Patients with Peripheral Arterial Disease and Type 2 Diabetes—Comorbidities and Concomitant Medications from the STRIDE Trial
Authors: RASOULI NEDA , CATARIG ANDREI-MIRCEA , HANSEN YASEMIN , HOULIND KIM , RAMESH CHETHANA , LUDVIK BERNHARD , NORDANSTIG JOAKIM , SOURIJ HARALD , VERMA SUBODH , BONACA MARC P. 
Published: June 2024

Lower extremity peripheral arterial disease (PAD) is caused by atherosclerosis of leg arteries and may result in severe functional impairment. People with type 2 diabetes (T2D) are at higher risk of developing PAD than those without T2D. We present baseline data from STRIDE, a phase 3 trial investigating functional outcomes of semaglutide treatment in patients with PAD and T2D. STRIDE enrolled 792 patients with PAD (Fontaine IIa claudication) and T2D who were randomized to either 1 mg once-weekly subcutaneous semaglutide or placebo for 52 weeks. The primary outcome is change in maximum walking distance on a constant load treadmill. Baseline characteristics, comorbidities and medications were recorded. Median age was 68, 75.4% male, a median duration of T2D of 12 years, mean HbA1c 7.3% and LDL-C 2.0 mmol/L. CVD related history included: hypertension (87.9%), coronary disease (42.4%), coronary revascularization (31.4%), MI (18.7%), coronary artery stenosis &gt;50% (27.5%), stroke (6.4%), transient ischemic attack (3.9%), chronic heart failure (13.6%), and chronic kidney disease (15.8%). More than a third were on SGLT2is. Baseline medications are shown in table 1. We highlight the high CVD burden and the baseline medications of patients in STRIDE, representing a study population with multiple comorbid risk factors and reasonably well controlled T2D.

Disclosure

N. Rasouli: Advisory Panel; Eli Lilly and Company, Novo Nordisk. Research Support; Novo Nordisk. A. Catarig: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. Y. Hansen: Employee; Novo Nordisk A/S. Stock/Shareholder; Novo Nordisk A/S. K. Houlind: Consultant; LeMaitre. C. Ramesh: None. B. Ludvik: Speaker's Bureau; Novo Nordisk. Research Support; Lilly Diabetes. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Bayer Inc. Speaker's Bureau; AstraZeneca. Research Support; Lilly Diabetes, Novo Nordisk, Boehringer-Ingelheim. Advisory Panel; Novo Nordisk, Lilly Diabetes. J. Nordanstig: Advisory Panel; AstraZeneca, Bayer Inc. Research Support; Artivion. H. Sourij: Advisory Panel; Amarin Corporation. Speaker's Bureau; Amgen Inc., Amarin Corporation, Bayer Inc. Advisory Panel; Boehringer-Ingelheim. Speaker's Bureau; Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim. Advisory Panel; Eli Lilly and Company. Research Support; Eli Lilly and Company. Speaker's Bureau; Eli Lilly and Company. Advisory Panel; Novartis AG. Speaker's Bureau; Novartis AG. Advisory Panel; Novo Nordisk. Research Support; Novo Nordisk. Speaker's Bureau; Novo Nordisk. Research Support; Sanofi. Speaker's Bureau; Sanofi. Consultant; K:Businesscom. S. Verma: Other Relationship; Amarin Corporation, Amgen Inc., AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly and Company, HLS Therapeutics Inc., Janssen Pharmaceuticals, Inc., Novartis AG, Novo Nordisk, Pfizer Inc., PhaseBio Pharmaceuticals, Inc., S&L Solutions Event Management, Sanofi. M.P. Bonaca: Other Relationship; CPC Clinical Research.